High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 4423-4427

  Re, Alessandro ^a   Cattaneo, Chiara ^b   Michieli, Mariagrazia ^b   Casari, Salvatore ^b   Spina, Michele ^b   Rupolo, Maurizio ^b   Allione, Bernardino ^b   Nosari, Annamaria ^b   Schiantarelli, Clara ^b   Viganò, Mariagrazia ^b   Izzi, Immacolata ^b   Ferremi, Piero ^b   Lanfranchi, Arnalda ^b   Mazzuccato, Maurizio ^b   Carosi, Gianpiero ^b   Tirelli, Umberto ^b   Rossi, Giuseppe ^b  

^a Divisione di Ematologia   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; CD34 ANTIGEN;

ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SALVAGE THERAPY; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; MULTICENTER STUDY; PATHOGENICITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VIRAL LOAD;

EID: 0642276781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.039     Document Type: Article

References (21)

1. Levine AM: Acquired immunodeficiency syndrome-related lymphoma: Clinical aspects. Semin Oncol 27:442-453, 2000
2. Tirelli U, Errante D, Dolcetti R, et al: Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 13:1758-1767, 1995
3. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non Hodgkin's lymphoma. Recent Results Cancer Res 159:143-148, 2002
4. Re A, Casari S, Cattaneo C, et al: Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 92:2739-2745, 2001
5. Oksenhendler E, Gerard L, Dubreuil ML, et al: Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma 39:87-95, 2000
6. Tirelli U, Spina M, Jaeger U, et al: Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Preliminary results of a phase I/II study. Recent Results Cancer Res 159:149-153, 2002
7. Spina M, Gabarre J, Rossi G, et al: Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100:1984-1988, 2002
8. Tirelli U, Errante D, Spina M, et al: Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer 77:2127-2131, 1996
9. Levine AM, Tulpule A, Tessman D, et al: Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter phase II trial. J Clin Oncol 15:1094-1103, 1997
10. Spina M, Vaccher E, Juzbasic S, et al: Human immunodeficiency virus-related non-Hodgkin lymphoma: Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 92:200-206, 2001
11. Bi J, Espina BM, Tulpule A, et al: High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 28:416-421, 2001
12. Philip T, Giglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
13. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease. Lancet 341:1051-1054, 1993
14. Gabarre J, Azar N, Autran B, et al: High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 355:1071-1072, 2000
15. Krishnan A, Molina A, Zaia J, et al: Autologous stem cell transplantation for HIV-associated lymphoma. Blood 98:3857-3859, 2001
16. Gribben JG, Goldstone AH, Linch DC, et al: Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol 7:1621-1629, 1989
17. Gabarre J, Choquet S, Azar N, et al: High dose chemotherapy with autologous stem cell transplantation (ASCT) for HIV-associated lymphoma (Ly). Blood 98:502a, 2001 (abstr 2092)
18. Krishnan A, Molina A, Zaia J, et al: Durable remissions in HIV-related lymphoma with autologous stem cell transplantation. Blood 100: 181a, 2002 (abstr 677)
19. Serrano D, Carrion R, Miralles P, et al: Autologous stem cell transplant (ASCT) in HIV-1+ high risk lymphoma patients. HIV infection does not preclude ASCT for lymphoma. Bone Marrow Transplant 29:588, 2002 (abstr 8437)
20. Weiss R, Mitros P, Arasteb K, et al: HIV related lymphoma: Changes in immune parameters and viral load during chemotherapy. Blood 96:134a, 2000 (abstr 578)
21. Rossi G, Donisi A, Casari S, et al: The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 86:2391-2397, 1999